Abstract：
ABO incompatibility has long been considered an absolute contraindication for kidney transplantation. However, with the increasing number of patients with ESRD in recent years, ABO-incompatible kidney transplantation (ABOi-KT) has expanded the types of donors by crossing the blood group barrier through preoperative desensitization therapy. At present, the desensitization protocols consist of removal of preexisting ABO blood group antibody titers and prevention of ABO blood group antibody return. Studies have suggested similar patient and graft survival among ABOi-KT and ABOc-KT recipients. In this review, we will summarize the effective desensitization regimens of ABOi-KT, aiming to explore effective ways to improve the success rate and the long-term survival rate of ABOi-KT recipients.
摘要：
ABO不相容一直被认为是肾移植的绝对禁忌症。然而,随着近年来ESRD患者数量的增加,ABO不相容的肾脏移植（ABOi-KT）通过术前脱敏治疗跨越血型屏障，扩大了供体类型。目前,脱敏方案包括去除先前存在的ABO血型抗体滴度和预防ABO血型抗体回流.研究表明，ABOi-KT和ABOc-KT接受者的患者和移植物存活率相似。在这次审查中,我们将总结ABOi-KT的有效脱敏方案，旨在探索提高ABOi-KT受者成功率和长期生存率的有效途径。
